![]() |
市場調查報告書
商品編碼
1382480
子宮肌瘤切除術市場 - 按產品、類型、最終用途 - 到 2032 年的全球預測Myomectomy Market - By Product, By Type, By End-use - Global Forecast to 2032 |
在機器人輔助和微創技術等先進手術技術的不斷開發和採用的推動下,子宮肌瘤切除術市場規模預計從 2023 年到 2032 年將以 8.6% 的CAGR擴大。機器人輔助手術、腹腔鏡檢查和先進影像技術的高度整合等創新正在改變對子宮肌瘤切除術的需求,以提高精確度、減少侵入性並縮短恢復時間,從而改善患者的治療效果。
此外,外科醫生在手術過程中受益於改進的可視化和控制,進一步促進了對技術先進方法的日益成長的偏好。例如,2022 年 11 月,奧林巴斯推出了新的微創手術替代方案 moresolution (TM) Power Morcellator,由 TROKAMED GmbH 生產,適用於接受低風險子宮切除術或子宮肌瘤切除術的患者。隨著醫療保健產業的不斷轉型,市場有望實現穩定成長。
子宮肌瘤切除術產業按產品類型、最終用途和地區細分。
根據產品類型,從 2023 年到 2032 年,諧波手術刀細分市場的市場規模可能會呈現 8.2% 的CAGR。諧波手術刀因其在子宮肌瘤切除術中提供精確性和微創性而受到關注,可減少失血並促進患者康復。隨著醫療保健提供者優先考慮先進技術來最佳化手術干預,對諧波手術刀的需求預計將會上升,以減少熱擴散並改善可視化,從而改善手術結果。
就最終用途而言,門診手術中心 (ASC) 領域的子宮肌瘤切除術行業預計在 2023 年至 2032 年間實現 8.5% 的CAGR。由於住院費用降低和恢復時間加快,人們對門診手術的偏好日益增加,這將有助於細分市場成長。與傳統醫院環境相比,ASC 為子宮肌瘤切除手術提供了更方便且更具成本效益的環境。為患者提供的可近性和效率以及為醫療保健提供者提供的簡化工作流程將促進該細分市場的成長。
從地區來看,亞太地區子宮肌瘤切除術市場在2022 年佔據了相當大的收入佔有率,由於人們的意識不斷提高、子宮肌瘤患病率不斷上升以及醫療基礎設施的進步,預計到2032 年將實現穩定成長。此外,隨著越來越多的女性尋求先進的醫療解決方案,中國和印度對子宮肌瘤切除術的需求尤其成長。有利的政府措施的湧入和創新外科技術的大量採用將進一步推動該地區行業的成長。
Myomectomy Market size is poised to expand at 8.6% CAGR from 2023-2032 driven by the ongoing development and adoption of advanced surgical technologies, such as robotic-assisted and minimally invasive techniques. Innovations, including robotic-assisted surgery, laparoscopy, and higher integration of advanced imaging techniques are transforming the demand for myomectomy procedures to offer increased precision, reduced invasiveness, and shorter recovery times for enhanced patient outcomes.
Moreover, surgeons are benefiting from improved visualization and control during the procedures, further contributing to the growing preference for technologically advanced approaches. For instance, in November 2022, Olympus introduced its new minimally invasive surgery alternative, moresolution™ Power Morcellator, produced from TROKAMED GmbH for patients undergoing low-risk hysterectomy or myomectomy. With the rising transformation of the healthcare sector, the market is poised to witness steady growth.
The myomectomy industry is segmented into product type, end-use, and region.
Based on product type, the market size from the harmonic scalpel segment is likely to showcase 8.2% CAGR from 2023-2032. Harmonic scalpel has gained prominence as it offers precision and minimal invasiveness in myomectomy procedures for reducing blood loss and enhancing patient recovery. With healthcare providers prioritizing advanced technologies to optimize surgical interventions, the demand for harmonic scalpels is expected to rise to offer reduced thermal spread and improved visualization for improved surgical outcomes.
In terms of end-use, the myomectomy industry from the ambulatory surgical centers (ASC) segment is set to attain 8.5% CAGR between 2023 and 2032. The increasing preference for outpatient procedures due to reduced hospitalization costs and quicker recovery times will contribute to the segment growth. ASCs offer more convenient and cost-effective environment for myomectomy procedures compared to traditional hospital settings. The accessibility and efficiency offered to patients and the access to streamlined workflow to healthcare providers will add to the segment growth.
Regionally, the Asia Pacific myomectomy market held sizable revenue share in 2022 and is estimated to record steady growth through 2032 owing to increasing awareness, the rising prevalence of uterine fibroids, and higher advancements in healthcare infrastructure. Additionally, with the growing female population seeking advanced healthcare solutions, the demand for myomectomy procedures is particularly rising in China and India. The influx of favorable government initiatives and the surging adoption of innovative surgical technologies will further propel the regional industry growth.